Discuss the regulatory and enforcement challenges in curbing the circulation of spurious drugs in India. Suggest reforms to strengthen the pharmaceutical supply chain.

A spurious drug is one manufactured under another drug's name, or passed off as its imitation or substitute [1]. The seizure of suspected spurious anti-cancer and anti-diabetic medicines worth ₹6.6 crore in Kolkata by CDSCO and the West Bengal drugs directorate [3] shows how counterfeits reach the sickest patients despite a framework built on the Drugs and Cosmetics Act, 1940.

Regulatory challenges

• Fragmented federal architecture: CDSCO sets standards and regulates new drugs and imports, while manufacturing and sale licensing rests with state drug controllers, producing uneven capacity and standards across states [1].
• Weak deterrence: basic spurious-drug offences attract imprisonment up to three years; harsher punishment applies only where grievous hurt or death results — disproportionate to crore-scale rackets [1].
• Capacity deficit: few drug inspectors and testing laboratories mean quality failures surface largely through post-market sampling, published as monthly Drug Alerts [1].

Enforcement challenges

• Unlicensed units operating outside the licensing net escape routine inspection, supplying hospitals and clinics through wholesale nexuses before detection [3].
• Fake import trails: consignments labelled as foreign-manufactured, without proof of lawful import, are deemed spurious — yet paperwork is easily fabricated [3].
• Reactive surveillance: risk-based inspections since December 2022 have covered 905 units and yielded 694 actions (stop-production orders, licence suspensions, show-cause notices) — corrective rather than preventive [2].

Reforms to secure the supply chain

• Scale traceability: extend Schedule H2 QR/barcode authentication — recently widened from the top 300 brands to all vaccines, antimicrobials, NDPS and anti-cancer drugs — towards full formulary coverage, patient-verifiable at point of sale [4].
• Proportionate penalties with fast-track special courts for organised counterfeiting.
• Institutional strengthening: fill inspector vacancies, expand testing labs, institutionalise joint CDSCO–state inspections, and publicise the whistleblower reward scheme [1].
• Mandate e-procurement records for hospitals to audit purchase trails.

Spurious drugs represent a governance failure at the intersection of federal fragmentation, weak deterrence and thin inspection capacity. A digitally traceable, adequately staffed and uniformly enforced regime can safeguard both the citizen's right to health under Article 21 and India's standing as the "pharmacy of the world".